Weight regain is a possibility with both medications when treatment ends, which is why obesity is increasingly treated as a chronic condition that benefits from long-term, supervised care
Lets break down some potential scenarios and what we know so far: If you have IBS-D (diarrhoea-predominant): Slowing down gastrointestinal transit could actually be beneficial in this case
If approved for both obesity and diabetes indications, Medicare patients with diabetes may get coverage while those with obesity alone are excluded
However, these drugs may eventually become illegal to compound, and weight loss clinics and providers with semaglutide patients under their care should consider these steps to prepare for the inevitability: Review current patient prescriptions and identify patients using compounded versions of semaglutide
As market competition intensifies within the weight loss and diabetes management segments, pricing strategies and increased cost transparency are becoming increasingly important for sustaining industry presence
Rather than jumping to the maximum dose as quickly as the prescribing guidelines allow, consider staying at each dose level for a longer period